Chardan Capital Lowers Seres Therapeutics (NASDAQ:MCRB) Price Target to $6.00

Seres Therapeutics (NASDAQ:MCRB) had its price target dropped by research analysts at Chardan Capital from $8.00 to $6.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price objective suggests a potential upside of 482.52% from the stock’s previous close.

Separately, Oppenheimer cut their price objective on Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, March 6th.

Seres Therapeutics Stock Up 37.4 %

Shares of MCRB stock opened at $1.03 on Wednesday. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $6.26. The company has a market cap of $155.54 million, a PE ratio of -1.14 and a beta of 2.16. The business’s 50 day moving average is $0.83 and its two-hundred day moving average is $1.06.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.50 million. As a group, equities analysts expect that Seres Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Trading of Seres Therapeutics

A number of hedge funds have recently bought and sold shares of MCRB. Hudson Bay Capital Management LP increased its holdings in shares of Seres Therapeutics by 127.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 1,999,800 shares of the biotechnology company’s stock worth $4,760,000 after purchasing an additional 1,119,800 shares during the period. Pennant Investors LP acquired a new position in shares of Seres Therapeutics during the fourth quarter valued at about $409,000. Graham Capital Management L.P. raised its position in shares of Seres Therapeutics by 731.3% during the third quarter. Graham Capital Management L.P. now owns 206,838 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 181,957 shares during the last quarter. Rafferty Asset Management LLC raised its position in shares of Seres Therapeutics by 21.1% during the third quarter. Rafferty Asset Management LLC now owns 936,382 shares of the biotechnology company’s stock valued at $2,229,000 after buying an additional 162,995 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new position in shares of Seres Therapeutics during the third quarter valued at about $280,000. 59.34% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.